Kymera Therapeutics (KYMR) Insider Booth Sells $8.3M of Stock

Bruce Booth Makes a Major Sale

On June 29, 2026, Bruce Booth sold 76,650 shares of Kymera Therapeutics, Inc. (NasdaqGM: KYMR) in a planned transaction valued at approximately $8.28 million, with an average sale price of $108.05 per share. This sale adds to a series of transactions by Booth in June, making it a notable insider activity as he adjusts his holdings in the company.

Insider Buying and Selling at Kymera Therapeutics, Inc.

Booth has been actively selling shares of Kymera Therapeutics this month. Just days before this sale, he sold 134,720 shares on June 24 for about $13.5 million and 548,321 shares on June 25 valued at approximately $65.1 million. These recent activities reflect a significant movement of shares, suggesting Booth is strategically managing his stake in the company.

Stock Movement and Current Position

As of the publication date, Kymera Therapeutics is trading at $114.67, close to its 52-week high of $130.05. The stock has been on a strong upward trend, reflecting investor confidence in the company’s clinical pipeline and strategic direction. The recent insider sales come at a time when the company is gaining attention for its innovative therapies targeting serious health conditions.

Analysts Set New Price Targets

Analysts are optimistic about Kymera Therapeutics. On October 9, 2026, Raymond James initiated coverage with an 'Outperform' rating and a price target of $140. Citigroup maintained a 'Buy' rating with a raised target of $150 on October 5, while Stifel also kept its 'Buy' rating with a target of $152. This positive sentiment from analysts indicates strong expectations for the company's future performance, particularly as it advances its clinical programs.

What Kymera Therapeutics, Inc. Does

Kymera Therapeutics, based in Watertown, Massachusetts, is focused on developing small molecule therapeutics that degrade disease-causing proteins. The company is currently advancing several clinical programs, including treatments for autoimmune diseases and various cancers. The recent insider sale by Booth reflects both the dynamic nature of insider trading and the ongoing developments within the company.

What's Ahead for Kymera Therapeutics, Inc.

Looking forward, investors will be watching for the next earnings report scheduled for November 3, 2026. The recent insider sales may be seen as part of normal trading activity, and it's important to note that these transactions may not reflect current holdings following the sales. With a strong analyst consensus and a promising pipeline, Kymera Therapeutics appears to be well-positioned in the biotechnology landscape.